期刊文献+

比较激素联合来氟米特与其他免疫抑制剂治疗特发性膜性肾病的网状meta分析 被引量:5

Reticular meta-analysis in comparing hormone combined with leflunomide and other immunosuppressants in the treatment of idiopathic membranous nephropathy
下载PDF
导出
摘要 目的系统评价激素联合来氟米特与其他免疫抑制剂比较治疗特发性膜性肾病的疗效。方法计算机检索中英文数据库,包括从建库至2021年3月31日发表的与激素联合来氟米特治疗特发性膜性肾病有关的随机对照研究,对纳入文献采用WinBugs 14.3和Stata 15.0软件进行网状meta分析。结果共纳入27个随机对照试验,包括1641例患者。网状meta分析显示:在均联合激素的基础上,随访至6个月的完全缓解率,来氟米特联合环孢素高于环磷酰胺[OR=3.06,95%CI(1.14,8.22),P=0.006];他克莫司高于来氟米特[OR=2.47,95%CI(1.31,4.64),P=0.016]或环磷酰胺[OR=2.92,95%CI(1.65,5.14),P=0.010]。累积排序概率曲线下面积(SUCRA)显示:来氟米特联合环孢素(SUCRA=82.5)的疗效最佳;总缓解率方面,他克莫司高于来氟米特[OR=2.26,95%CI(1.27,4.00),P=0.030],他克莫司或来氟米特联合环孢素均高于环磷酰胺[OR=2.46,95%CI(1.45,4.19),P=0.012;OR=3.69,95%CI(1.49,9.15),P=0.003];来氟米特联合环孢素疗效最佳(SUCRA=92.3)。在不良反应方面,他克莫司发生肝酶异常(SUCRA=83.2)和白细胞减少(SUCRA=97.3)的风险最低,来氟米特最不易出现消化道反应(SUCRA=76.6)。结论在联合激素治疗特发性膜性肾病的基础上,来氟米特的疗效优于环磷酰胺;来氟米特联合环孢素在短期内的疗效与他克莫司不相上下,且均优于单独使用来氟米特或环磷酰胺,其长期疗效未来仍需更多高质量研究予以探究。 Objective To systematically evaluate the therapeutic efficacy of hormone combined with leflunomide compared with other immunosuppressants in the treatment of idiopathic membranous nephropathy.Methods The Chinese and English databases were searched by computer,including the randomized controlled research related to hormone combined with leflunomide in the treatment of idiopathic membranous nephropathy published from the establishment of the database to March 31,2021.The included literatures were performed by reticular meta-analysis by using WinBugs 14.3 and Stata 15.0 software.Results A total of 27 randomized controlled trials were fitted in,including 1641 patients.Reticular meta-analysis showed that on the basis of all combined hormones,the complete remission rate of leflunomide combined with cyclosporine was higher than that of cyclophosphamide(OR=3.06,95%CI[1.14,8.22],P=0.006).Tacrolimus was higher than leflunomide(OR=2.47,95%CI[1.31,4.64],P=0.016)or cyclophosphamide(OR=2.92,95%CI[1.65,5.14],P=0.010).The area under cumulative ranking probability curve(SUCRA)showed that leflunomide combined with cyclosporine(SUCRA=82.5)had the best therapeutic efficacy.In terms of total remission rate,tacrolimus was higher than leflunomide(OR=2.26,95%CI[1.27,4.00],P=0.030);Tacrolimus or leflunomide combined with cyclosporine are higher than cyclophosphamide(OR=2.46,95%CI[1.45,4.19],P=0.012;OR=3.69,95%CI[1.49,9.15],P=0.003).Leflunomide combined with cyclosporine had the best therapeutic efficacy(SUCRA=92.3).In terms of adverse reactions,tacrolimus had the lowest risk of liver enzyme abnormality(SUCRA=83.2)and leukopenia(SUCRA=97.3),and leflunomide was the least prone to gastrointestinal reactions(SUCRA=76.6).Conclusion On the basis of combined hormone therapy for idiopathic membranous nephropathy,leflunomide is more effective than cyclophosphamide.The short-term therapeutic efficacy of leflunomide combined with cyclosporine is comparable to that of tacrolimus,and they are both superior to that of leflunomide or cyclophosphamide alone.The long-term therapeutic efficacy of leflunomide combined with cyclosporine still needs more highquality research in the future.
作者 饶思捷 李云云 关扬婷 沈清 RAO Sijie;LI Yunyun;GUAN Yangting;SHEN Qing(Department of Nephrology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China;Yongchuan Hospital of Chongqing Medical University,Chongqing 402160,China)
出处 《中国医药科学》 2021年第24期42-47,145,共7页 China Medicine And Pharmacy
基金 国家自然科学基金(81902645)。
关键词 激素 来氟米特 特发性膜性肾病 网状meta分析 Hormones Leflunomide Idiopathic membranous nephropathy Reti cular meta-analysis
  • 相关文献

参考文献23

二级参考文献160

共引文献147

同被引文献111

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部